iRhythm Holdings, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
iRhythm Holdings, Inc. (IRTC) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $299.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-08-06
- iRhythm Holdings, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2026-06-30 was $299.00K, a 82.39% decline year-over-year.
- iRhythm Holdings, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2026-03-31 was $296.00K, a 0.00% change year-over-year.
- iRhythm Holdings, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $740.00K, a 145.03% increase year-over-year.
- iRhythm Holdings, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-09-30 was $302.00K, a 99.06% decline year-over-year.
- iRhythm Holdings, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2025 was $3.04M, a 90.62% decline from fiscal 2024.
- iRhythm Holdings, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $32.37M.
- iRhythm Holdings, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $0.00.
- iRhythm Holdings, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2026-06-30 | $299.00K 10-Q · filed 2026-08-06 | $595.00K 10-Q · filed 2026-08-06 | $1.33M derived: sum of 3 quarters · filed 2026-08-06 | $1.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $296.00K 10-Q · filed 2026-04-30 | $1.04M derived: sum of 2 quarters · filed 2026-04-30 | $1.34M derived: sum of 3 quarters · filed 2026-04-30 | $3.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $740.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.04M derived: sum of 2 quarters · filed 2026-02-19 | $2.74M derived: sum of 3 quarters · filed 2026-08-06 | $3.04M 10-K · filed 2026-02-19 |
| 2025-09-30 | $302.00K 10-Q · filed 2025-10-30 | $2.00M derived: sum of 2 quarters · filed 2026-08-06 | $2.30M 10-Q · filed 2025-10-30 | $2.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.70M 10-Q · filed 2026-08-06 | $1.99M 10-Q · filed 2026-08-06 | $2.30M derived: sum of 3 quarters · filed 2026-08-06 | $34.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $296.00K 10-Q · filed 2026-04-30 | $598.00K derived: sum of 2 quarters · filed 2026-04-30 | $32.67M derived: sum of 3 quarters · filed 2026-04-30 | $32.67M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $32.37M derived: sum of 2 quarters · filed 2026-02-19 | $32.37M derived: sum of 3 quarters · filed 2026-02-19 | $32.37M 10-K · filed 2026-02-19 |
| 2024-09-30 | $32.07M 10-Q · filed 2025-10-30 | $32.07M derived: sum of 2 quarters · filed 2025-10-30 | $32.07M 10-Q · filed 2025-10-30 | $32.07M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $0.00 10-Q · filed 2025-07-31 | $0.00 10-Q · filed 2025-07-31 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-10-30 | $0.00 10-Q · filed 2024-10-30 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PULSE BIOSCIENCES, INC. (PLSE) | United States | $3.696B | -24.47 |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |
| AtriCure, Inc. (ATRC) | United States | $3.089B | |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 |